Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Chen, Shuzhen ^a   Fu, Lei ^a   Raja, Shruti M ^a   Yue, Ping ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; GERANYLGERANYLTRANSFERASE 1; GGTI 298; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; TRANSFERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CFLAR PROTEIN, HUMAN; GERANYLGERANYLTRANSFERASE TYPE I; GERANYLGERANYLTRANSFERASE TYPE-I; GGTI DU40; GGTI-DU40; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE; UPREGULATION;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; I-KAPPA B PROTEINS; LUNG NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIDINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RHOB GTP-BINDING PROTEIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 77349093082     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-23     Document Type: Article

References (37)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407:770-776. 10.1038/35037710, 11048727.
2. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001, 21:8247-8254. 10.1128/MCB.21.24.8247-8254.2001, 99990, 11713262.
3. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004, 4:333-339. 10.1016/j.coph.2004.02.006, 15251125.
4. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12:228-237. 10.1038/sj.cgt.7700792, 15550937.
5. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, Huw L, Katta V, Cavet G, Hymowitz SG, Amler L, Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007, 13:1070-1077. 10.1038/nm1627, 17767167.
6. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22:8628-8633. 10.1038/sj.onc.1207232, 14634624.
7. Philips MR, Cox AD. Geranylgeranyltransferase I as a target for anti-cancer drugs. J Clin Invest 2007, 117:1223-1225. 10.1172/JCI32108, 1857249, 17476354.
8. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000, 19:6584-6593. 10.1038/sj.onc.1204146, 11426643.
9. El Oualid F, Cohen LH, Marel GA, Overhand M. Inhibitors of protein: geranylgeranyl transferases. Curr Med Chem 2006, 13:2385-2427. 10.2174/092986706777935078, 16918362.
10. Lerner EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 1995, 270:26770-26773. 10.1074/jbc.270.45.26770, 7592913.
11. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM, Dalin M, Weinbaum C, Casey PJ, Tarkowski A, Swolin B, Young SG, Bergo MO. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 2007, 117:1294-1304. 10.1172/JCI30868, 1857236, 17476360.
12. Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 2003, 63:8922-8929.
13. Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003, 102:3354-3362. 10.1182/blood-2003-03-0970, 12855556.
14. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004, 23:706-715. 10.1038/sj.onc.1207171, 14737105.
15. Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 1997, 57:1846-1850.
16. Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002, 277:15309-15316. 10.1074/jbc.M201253200, 11839765.
17. Peterson YK, Kelly P, Weinbaum CA, Casey PJ. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 2006, 281:12445-12450. 10.1074/jbc.M600168200, 16517596.
18. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res 2006, 66:11115-11119. 10.1158/0008-5472.CAN-06-2471, 17145853.
19. Zou W, Liu X, Yue P, Khuri FR, Sun SY. PPARgamma Ligands Enhance TRAIL-induced Apoptosis through DR5 Upregulation and c-FLIP Downregulation in Human Lung Cancer Cells. Cancer Biol Ther 2007, 6:99-106.
20. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, Hong WK, Lotan R. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997, 57:4931-4939.
21. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999, 18:2357-2365. 10.1038/sj.onc.1202543, 10327056.
22. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004, 96:1769-1780.
23. Jin F, Liu X, Zhou Z, Yue P, Lotan R, Khuri FR, Chung LW, Sun SY. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 2005, 65:6354-6363. 10.1158/0008-5472.CAN-04-4061, 16024638.
24. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007, 67:4981-4988. 10.1158/0008-5472.CAN-06-4274, 17510429.
25. Qiu Y, Liu X, Zou W, Yue P, Lonial S, Khuri FR, Sun SY. The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer Res 2007, 67:4973-4980. 10.1158/0008-5472.CAN-06-4044, 17510428.
26. Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR. The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells. J Biol Chem 2007, 282:18800-18809. 10.1074/jbc.M611438200, 17493934.
27. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 2005, 16:55-76. 10.1016/j.cytogfr.2004.12.001, 15733832.
28. Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, Chellappan S, Sebti SM. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene 2007, 26:633-640. 10.1038/sj.onc.1209819, 16909123.
29. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005, 25:31-58. 10.1615/CritRevImmunol.v25.i1.30, 15833082.
30. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997, 7:831-836. 10.1016/S1074-7613(00)80401-X, 9430228.
31. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997, 7:821-830. 10.1016/S1074-7613(00)80400-8, 9430227.
32. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005, 9:59-71. 10.1111/j.1582-4934.2005.tb00337.x, 15784165.
33. Du W, Liu A, Prendergast GC. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999, 59:4208-4212.
34. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000, 20:139-148. 10.1128/MCB.20.1.139-148.2000, 85069, 10594016.
35. Sun SY, Zhou Z, Wang R, Fu H, Khuri FR. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biol Ther 2004, 3:1092-1098. discussion 1099-1101.
36. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998. 10.1038/sj.onc.1207115, 14663477.
37. McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem 1996, 271:27402-27407. 10.1074/jbc.271.44.27402, 8910319.